Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded down 19.4% on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares were traded during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Trading Down 19.4 %
The firm has a market capitalization of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20. The business’s 50-day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- High Flyers: 3 Natural Gas Stocks for March 2022
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- 3 Grocery Stocks That Are Proving They Are Still Essential
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Manufacturing Stocks Investing
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
